Brief: Xspray Pharma's XS003 Study Shows Matching Bioavailability To Tasigna At More Than A 50% Lower Dose
09/07/2024 19:33
July 9 (Reuters) - XSpray Pharma AB XSPRAY.ST :
* XSPRAY PHARMA AB: XS003 STUDY SHOWS MATCHING
BIOAVAILABILITY TO
TASIGNA AT MORE THAN A 50% LOWER DOSE
* XSPRAY PHARMA AB: TO SUBMIT APPROVAL APPLICATION FOR XS003
TO
FDA IN FIRST HALF OF 2025
Source text for Eikon: ID:nBw8wFs7Ga
Further company coverage: XSPRAY.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003